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From stocks of adenovirus and poliovirus prepared in primary rhesus macaque kidney cells and dating from 1956 to 1961, the time when SV40
contaminated some poliovirus vaccine lots, we have recovered ten isolates of SV40. Of these ten isolates, based on the C-terminal region of T
antigen, five novel strains of SV40 have been identified. Additionally, three pairs of isolates were found to be the same strain: one pair was strain
777, one pair was strain 776 archetype, and the third pair represented a novel strain. All strains had identical protein sequences for VP2 and VP3.
There were two variants of agnoprotein and the small t antigen and three variants of VP1. These results, and those of others, suggest that a limited
number of SV40 strains might exist in rhesus macaques in the United States, and thus determining the origin of the SV40 sequences detected in
human tumors might be difficult.
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Some lots of the inactivated poliovirus vaccine (IPV) and
some clinical lots of the live, attenuated, oral poliovirus vaccine
(OPV) were contaminated with SV40, a polyomavirus that is an
infectious agent of rhesus macaques (Lapin et al., 1965;Meyer et
al., 1962; Shah and Southwick, 1965), the source of the primary
kidney cells used for vaccine manufacture (Lewis, 1973; Shah
and Nathanson, 1976; Sweet and Hilleman, 1960). After the
identification of SV40 as a contaminant, all inactivated polio-
virus vaccines manufactured in the United States from 1961⁎ Corresponding author. Fax: +1 301 496 1810.
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doi:10.1016/j.virol.2007.06.045were required to be free of this virus (Murray, 1961), although
due to the 2-year shelf life of these vaccines, some SV40-con-
taminated lots of IPV could have been used until 1963 (Shah and
Nathanson, 1976). At the time when OPV was licensed in the
United States, all lots were tested to be free of SV40.
Apart from SV40, a number of primate polyomaviruses have
been isolated. JCV (Padgett et al., 1971) and BKV (Coleman et
al., 1973) are human viruses; SA12 (Valis et al., 1977) is a
baboon virus; and SLPV (zur Hausen and Gissmann, 1979) is an
African green monkey virus. As far as can be ascertained,
polyomaviruses in their natural hosts generally do not cause
disease and remain clinically latent (Chesters et al., 1983;
Heritage et al., 1981; Monaco et al., 1996). However, when
humans are immunocompromised, polyomaviruses can cause
serious disease. For example, JCV can cause the fatal demye-
linating disease progressive multifocal leukoencephalopathy
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significant cause of renal transplant failure (Ahsan and Shah,
2006; Hirsch and Steiger, 2003) and the cause of hemorrhagic
cystitis after bone marrow transplantation (Ahsan and Shah,
2006; Bogdanovic et al., 1998; Fioriti et al., 2005). Similarly, in
rhesus macaques that have been immunocompromised follow-
ing infection with either simian immunodeficiency virus (SIV)
or simian/human immunodeficiency virus (SHIV), the presence
of SV40 infection can result in a PML-like disease (Chrétien et
al., 2000; Holmberg et al., 1977; Horvath et al., 1992; King et al.,
1983), demonstrating that SV40, like JCV, can be neurotropic.
The main reason for the renewed interest in SV40 biology
has been the finding that SV40 sequences can be detected in
certain human tissues or tumors. Over 30 years ago, using
techniques that did not involve PCR amplification, SV40 was
reported to be isolated from two patients with PML (Narayan
and Weiner, 1974; Sack et al., 1973; Weiner et al., 1972) and
was reported to be in tumors of the brain (Krieg and Scherer,
1984; Krieg et al., 1981). More recently, using DNA molecular
amplification methods, the presence of SV40 sequences has
been reported in samples obtained from a variety of human
tumors including choroid plexus tumors (Bergsagel et al., 1992;
Lednicky et al., 1995a), ependymomas (Bergsagel et al., 1992;
Lednicky et al., 1995a), mesotheliomas (Barbanti-Brodano et
al., 1998; Carbone et al., 1994; Pepper et al., 1996; Rizzo et al.,
1998, 1999a; Vilchez and Butel, 2003a), osteosarcomas
(Carbone et al., 1996; Heinsohn et al., 2000; Lednicky et al.,
1997; Rizzo et al., 1998), glioblastomas (Kouhata et al., 2001),
and non-Hodgkin's lymphomas (Butel et al., 2003; Vilchez and
Butel, 2003b). In addition, SV40 has been reported to be present
in patients with renal allografts and focal segmental glomerulo-
sclerosis (Li et al., 2002a,b). SV40 DNA sequences have also
been reported to be present in the peripheral blood mononuclear
cells of normal donors (Martini et al., 2002) and recently in the
urine (Vanchiere et al., 2005b) and stools (Vanchiere et al.,
2005a) of children.
Because many of the people with tumors and renal disease
whose tissues reportedly contain SV40 sequences were born
after SV40 was no longer a contaminant of poliovirus vaccines,
the origin of the SV40 in these individuals is unknown. One
hypothesis is that SV40 was introduced to humans via con-
taminated vaccines and subsequently became a human infec-
tious agent. However, not all investigators believe that SV40 is a
human infectious agent or is involved in human cancer (Shah et
al., 1997; Strickler et al., 1996), and some even suggest that most
if not all PCR detection is explained by contamination (Lopez-
Rios et al., 2004). The origin of SV40 sequences in tumors and
whether SV40 is an infectious agent of humans have been the
subject of an Institute of Medicine report (Stratton et al., 2003).
Because of the controversy with respect to SV40 and human
infection, we are looking for ways to demonstrate whether SV40
could be an infectious agent of humans and whether SV40 was
introduced to humans via contaminated vaccines. To address the
issue of whether SV40 is circulating in humans, we are
developing serological assays that might be able to document
the presence of antibodies, specifically neutralizing antibodies,
to the primate polyomaviruses (Sheng et al., in preparation; Palet al., in preparation). A second approach that might be able to
demonstrate an association between poliovirus vaccination and
human cancer would be to demonstrate identity between SV40
strains present in human tumors and those present in the
poliovirus vaccines. Unfortunately, vaccines from that time have
been difficult if not impossible to locate (Rizzo et al., 1999b).
Therefore, we took an alternative approach. If it could be shown
that the DNA sequences of the SV40 strains circulating in rhesus
macaques in the 1950s to 1961 were identical and limited to
those found in human tumors, this would add weight to the
argument that the source of the SV40 in human tumors was
contaminated poliovirus vaccines.
We had available to us some adenovirus and poliovirus stocks
that had been propagated on primary rhesus monkey kidney cells
from the 1950s to the early 1960s. The genomes of the viruses
were cloned and their complete sequences determined. While
two of the SV40 strains that we recovered from the stocks had
already been described, five novel strains were identified. From
these results and those published, there appears to be a limited
number of SV40 strains, at least those present in the monkeys
imported into the United States. In addition, because all VP1
genes are highly conserved in these strains and in all those strains
that have been reported from natural isolates, we conclude that
SV40 is likely a single serotype.
Results
Isolation of SV40 from poliovirus and adenovirus stocks
The stocks of adenovirus type 3 (Ad3), adenovirus type 4
(Ad4), adenovirus type 6 (Ad6), and adenovirus type 7 (Ad7)
were from the collection of Janet Hartley (NIAID, NIH) (Hartley
et al., 1956), and the poliovirus stocks of type I, type II, and type
III were identified at the Center for Biologics Evaluation and
Research (CBER) (Table 1). It is important to emphasize that the
polioviruses are not vaccine strains but are wild-type strains.
Prior to the attempted isolation of SV40, we used real-time
quantitative PCR to determine whether SV40 was present in the
stocks and to estimate the number of viral genomes in each
stock. These results demonstrated that SV40DNAwas present in
all adenovirus and poliovirus stocks, although the amount of
DNAvaried (Table 1). In all cases, higher copy numbers of SV40
genomes were present in the adenovirus stocks compared with
the poliovirus stocks. SV40 was recovered from all of the
adenovirus stocks except the Ad6 stock, which had 19,400 SV40
genome copies per μL stock, and all of the poliovirus stocks
except poliovirus type IIIA stock from 1961, which had 0.2
SV40 genome copies per μL stock (Table 1).
Given the controversy over the presence of SV40 sequences
in human tumors and tissues, care was taken at all stages of
infection, virus production, and DNA preparation to ensure the
absence of contamination. Viruses were recovered in a former
containment laboratory that had never been used for the
propagation of infectious agents. SV40 was recovered from
the poliovirus and adenovirus stocks on different days, with all
surfaces being decontaminated with 10% sodium hypochlorite
between all manipulations.
Fig. 1. Restriction enzyme analysis of the Hirt DNA from the adenovirus and
poliovirus stocks. Low-molecular weight DNA was isolated and purified from
infected cells by a modification of the Hirt method. Five microliters of the Hirt
DNAwas digested either with BamHI or EcoRI and analyzed by electrophoresis
on a 1% agarose gel. Lanes indicated M contain 1-kb size markers. Lane a: Ad3
stock; lane b: Ad4 stock; lane c: Ad7 stock; lane d: uninfected CV1 cells; lane e:
poliovirus type I stock from 1961; lane f: poliovirus type II stock from 1961;
lane g: poliovirus type III stock A from 1961; lane h: poliovirus type I stock
from 1957; lane i: poliovirus type II stock from 1957; lane j: poliovirus type III
stock B from 1961.
Table 1
Source of the viral stocks and designations of SV40
Virus stock Date of origin Source Copy number of SV40
Genomes (per μL stock)
Isolate designation Strain GenBank accession
number
Adenovirus type 3 1956 NIAID 22.4×106 SV(Ad)191 Novel EF579658
Adenovirus type 4 1956 NIAID 17.9×106 SV(Ad)201 a Novel EF579659
Adenovirus type 6 1956 NIAID 19.4×103 – – –
Adenovirus type 7 1956 NIAID 5.4×106 SV(Ad)211 Novel EF579660
SV(Ad)212a Novel EF579661
Poliovirus Type I 1961 CBER 8.6 SV(PV)232 Novel EF579662
SV(PV)236 776 EF579663
Poliovirus Type II 1961 CBER 1312 SV(PV)241 Novel EF579664
Poliovirus Type IIIA 1961 CBER 0.2 – – –
Poliovirus Type I 1957 CBER 200 SV(PV)251 777 EF579665
Poliovirus Type II 1957 CBER 660 SV(PV)264 777 EF579666
Poliovirus Type IIIB 1961 CBER 27.4 SV(PV)274 776 EF579667
a Same strain.
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used CV-1 cells, a cell line of African green monkey kidney cells
permissive for SV40 replication. Before infection, the adeno-
viruses and polioviruses present in the stocks were inactivated.
Heat inactivation alone (56 °C for 10 min) was used for
adenovirus, whereas heating (50 °C for 15 min) plus treatment
with type-specific neutralizing monoclonal antibodies for
30 min at 37 °C was used for poliovirus elimination. When the
cytopathic effect (CPE) in the CV-1 cultures was extensive (+3
to +4), the flasks were frozen; this material became the initial
SV40 stocks. CPE was noted in all cultures except from the Ad6
stock and the poliovirus type IIIA stock.
Molecular cloning of the SV40 genomes
Because of the potential that in vitro propagation could result
in an alteration of the virus populations compared with those
present in the rhesus monkey kidney cells, we cloned the SV40
genomes as soon as practical. This potential alteration in the
SV40 populations would arise through the selection of viruses
better able to replicate in CV-1 cells in vitro, either by the
selection of pre-existing viruses or, less likely, by the selection
of new variants following mutation. Low-molecular weight
(Hirt) DNA was prepared from CV-1 cells infected with the
initial virus stocks when CPE was apparent but not extensive
(+2). Analysis of this DNA by agarose–gel electrophoresis
demonstrated that extrachromosomal DNA migrating at
approximately 5 kilobase pairs (kb) was present in all samples
(data not shown). To determine which enzyme would be
suitable to clone the genomes, the Hirt DNA was digested
separately with BamHI and EcoRI, enzymes known to cleave
all known full-length SV40 genomes once. All of the 5-kb
species were digested to a single fragment with both enzymes
(Fig. 1). In the DNA derived from the Ad7 stock, a second band
migrating around 4.5 kb was observed in the BamHI digest. In
the EcoRI digest, this DNA migrated as form I and form II
species, indicating that no EcoRI site was present in this smaller
genome. Therefore, BamHI was chosen as the cloning enzyme.
Approximately 5 μg of the Hirt DNAwas digested with BamHI,
the 5-kb fragments (and the 4.5 kb fragment from the Ad7stock) were gel purified, and ligated into BamHI-digested
pBluescript.
Restriction analysis of the cloned SV40 genomes
As a first step in confirming that the genomes were indeed
SV40 and to determine whether gross polymorphisms could be
identified, restriction enzyme analysis with HindIII and with
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are shown in Fig. 2. All but two clones (Fig. 2, lanes g and h)
contained a similar distribution of fragments. The exceptions,
clones 1222-1 and 1222-2, were obtained from the smaller
species found in the Ad7 stock; this genome was not infectious
and will not be considered further. Of the clones with the 5-kb
genomes, two fragments were polymorphic; fragment C and
fragment D migrated differently in the digests of the clones.
These fragments correspond to the control region (fragment C)
and the C-terminal region of the T antigen gene (fragment D),
both regions where polymorphisms in SV40 isolates have been
documented. The fragment corresponding to the control region
(fragment C) of all the clones is smaller than the corresponding
one from strain 776 (Fig. 2, lane t), indicating that none of the
strains has two complete copies of the 72-bp enhancer.
Fragment C in clone pSV(Ad)211 (Fig. 2, lane e) migrated
slightly more slowly than those of the other clones, suggesting
that this clone might contain more than one copy of the 72-bpFig. 2. Restriction enzyme analysis of the cloned SV40 DNA. Two molecular
clones of SV40 from each adenovirus or poliovirus stock were digested with
BamHI plus HindIII. The digestion products were fractionated by electro-
phoresis on a 1.8% agarose gel. Lanes indicated M contain 1-kb size markers.
Lanes a and b: clones pSV(Ad)191 and pSV(Ad)192 (from the Ad3 stock);
lanes c and d: clones pSV(Ad)201 and pSV(Ad)203 (from the Ad4 stock);
lanes e and f: clones pSV(Ad)211 and pSV(Ad)212 (from the Ad7 stock);
lanes g and h: clones 1222-1 and 1222-2 (from the Ad7 stock); lanes i and j:
clones pSV(PV)232 and pSV(PV)234 (from the poliovirus type I 1961 stock);
lanes k and l: clones pSV(PV)241 and pSV(PV)242 (from the poliovirus type
II 1961 stock); lanes m and n: clones pSV(PV)251 and pSV(PV)252 (from
the poliovirus type I 1957 stock); lanes o and p: clones pSV(PV)264 and pSV
(PV)266 (from the poliovirus type II 1957 stock); lanes q and r: clones pSV
(PV)272 and pSV(PV)274 (from the poliovirus type III 1961 stock); lane t:
the pSVB3 clone of strain 776.enhancer region but not two copies. The remaining clones
appeared to have a single element and likely have an archetype
arrangement of the enhancer element. The other fragment that
displayed polymorphism was the one that contained the
C-terminal part of the T antigen gene (fragment D). This region
is the main polymorphic region of wild-type SV40 strains
(Forsman et al., 2004; Ilyinskii et al., 1992; Stewart et al.,
1996), and several clones displayed heterogeneity in the pattern
of electrophoretic migration. This restriction analysis confirmed
that the clones were indeed SV40 and demonstrated that several
different genomes had been recovered.
The cloned genomes encode functional viruses
Before determining the sequence of the SV40 genomes, it
was necessary to ascertain that the viral genomes cloned were
biologically active. DNAwas released from the plasmid vector
by BamHI digestion, the DNA was ligated to circles, and this
DNAwas used to transfect CV-1 cells. From the appearance of
CPE in the cultures beginning at about day 7, it was clear that all
of the 5-kb genomes were biologically active. The smaller DNA
species present in the Ad7 stock was not infectious.
Sequencing of the genomes revealed the existence of
new strains
Because the terms isolates, strains, and genotypes have been
used inconsistently, we have used them as described inMaterials
and methods. The complete sequences of the cloned genomes of
the ten isolates that encoded infectious viruses were determined
using the oligonucleotide primers listed in Table 2; these primers
were spaced approximately 400 bp apart on each strand with a
stagger of about 100 bp on the other strand, thus providing
substantial overlap of sequences. Any sequence changes from
strain 776 were confirmed by additional sequencing. For some
clones, sequence deviations from strain 776 were confirmed by
sequencing other molecular clones obtained from the same
stocks. The nucleotide differences of the isolates (excluding the
control region) from 776 are presented in Table 3, where the
numbering is according to strain 776. The results demonstrated
the following:
1. Of the eight stocks, a single SV40 isolate was recovered
from six, while two stocks – the Ad7 stock and the
poliovirus type I stock from 1961 – each contained two
different strains of SV40 (Tables 3A and 3B).
2. The large T antigen protein sequence in all strains was
identical up to the Gly residue at position 622, after
which polymorphisms were observed. This C-terminal
region has been found to display significant polymorph-
ism and is the main region by which strain assignments
have been made (Forsman et al., 2004; Ilyinskii et al.,
1992; Stewart et al., 1996). This region of the various T
antigens is aligned in Fig. 3.
3. Considering only the protein sequences, of the ten
isolates, three pairs were found to be the same [SV(Ad)
201 and SV(Ad)212, SV(PV)236 and SV(PV)274, and
Table 2
Sequences and location of the primers used for sequencing
Primer
number
Sequence Position on genome Size
(nucleotides)
Start Finish
Oligo540 TTAGCTGCAAAGATTCCTCTCTG 5124 5146 23
Oligo541 CAGCATAGGCCTGTGGAGTGAG 766 745 22
Oligo544 AGACATGATAAGATACATTGATGAG 2539 2563 25
Oligo545 TACAGACCTGTGGCTGAGTTTGC 3074 3052 23
Oligo550 AGTTAGGGGCGGGACTATGGTTGC 90 113 24
Oligo551 TAACTGAAAAACCAGAAAGTTAACTGG 501 527 27
Oligo552 TATCAACAACCAGGAATGGCTGTAG 901 925 25
Oligo553 ATAATATTGATGAAGCAGACAGTATTC 1301 1327 27
Oligo554 TAAGTAAAAGCTTAGCAGCTGAAAAAC 1701 1727 27
Oligo555 TAAGGATAATGCTTATCCAGTGGAG 2101 2125 25
Oligo556 AGGGTTTATGAGGACACAGAGGAGC 2501 2525 25
Oligo557 GCTGTCTTCATCATCATCATCACTG 2901 2925 25
Oligo558 TTAACACTGCCATCCAAATAATCCC 3301 3325 25
Oligo559 CCATCCTATCCAAAAGATCATTAAATC 3701 3727 27
Oligo560 ATCTCTAGTCAAGGCACTATACATC 4101 4125 25
Oligo561 GAGCAAAACAGGTTTTCCTCATTAAAG 4501 4527 27
Oligo562 AAGGAAGAAGCAAATACCTCAGTTGC 4901 4926 26
Oligo563 GAGCTATTCCAGAAGTAGTGAGGAG 5230 5206 25
Oligo564 GCTGTGCTTACTGAGGATGAAGC 4822 4800 23
Oligo565 GTAGAAGACCCCAAGGACTTTCCTTC 4424 4399 26
Oligo566 TAAACAAGTGTCCTGGAAGCTTG 4023 4001 23
Oligo567 CAAAATGGATTCAGTGGTGTATG 3621 3599 23
Oligo568 GTGTGCCTAAAACACTGCAGGCC 3223 3201 23
Oligo569 CAGTCCCAAGGCTCATTTCAGGC 2822 2800 23
Oligo570 CTTAACAAAAAGGAAATTGGGTAG 2424 2401 24
Oligo571 TATTTGGTCCTGTAGTTTGCTAAC 2022 1999 24
Oligo572 GTTTTAACTCCTAGAACTTCTATTC 1623 1599 25
Oligo573 AAGTAGAGTAGTAATCTTGTAAAG 1222 1199 24
Oligo574 GTCACAGTTTGCAGTAAAGCTGC 826 801 23
Oligo578 CTATAGCAGCAATTGCCTCAG 742 722 21
Oligo575 AACAAACACAAAAAGGCGTTGAGC 430 407 24
Oligo576 CGACGGTATCGATAAGCTTG 737 718 20
Oligo577 CGTAATACGACTCACTATAG 624 643 20
All primers except Oligo576 and Oligo577 are to SV40 776.
Oligo576 and Oligo577 are to pBluescript.
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strains; these pairs of identical isolates were obtained
from different stocks. In one identical pair, one isolate
was from an adenovirus type 4 stock, the other was from
an Ad7 stock [SV(Ad)201 and SV(Ad)212, respec-
tively]. In a second identical pair, one isolate was from a
poliovirus type I stock, the other from a type II stock
[SV(PV)251 and SV(PV)264, respectively], and these
strains were strain 777. In the third identical pair, one
isolate was from a poliovirus type I stock, the other from
a type III stock [SV(PV)236 and SV(PV)274, re-
spectively], and these strains were archetype versions of
strain 776.
4. Of the ten isolates, five new strains were identified. These
are SV(Ad)191, SV(Ad)201/SV(Ad)212, SV(Ad)211, SV
(PV)232, and SV(PV)241.
5. Considering the nucleotide sequences, SV(Ad)201 and SV
(Ad)212 are not only the same strain but are also the same
genotype, since they are identical at the nucleotide level.
SV(PV)236 and SV(PV)274 are both archetype versions
of strain 776, but while SV(PV)274 is identical to 776 atthe nucleotide level (excluding the control region), SV
(PV)236 has a single nucleotide difference in the Tantigen
gene. This silent nucleotide change is the same one as
found in H328, an isolate from an SIV-infected monkey
(Lednicky et al., 1998), and thus SV(PV)236 and H328 are
the same genotype. In the case of the 777 strains SV(PV)
251 and SV(PV)264, their genotypes are different, since
there are differences between their nucleotide sequences
and those of 777 and from SVCPC, SVMEN,
GM000637H, N128, and Rh911, all of which are other
isolates of strain 777 (Table 4).
6. All genomes except one had the archetype arrangement of
their enhancer regions. The exception, SV(Ad)211, was
non-archetype and had two incomplete copies of the
enhancer element such that one was 45 bp in length and the
other was 46 bpwith a deletion of 53 bp in between the two
enhancer elements (Fig. 4). None had two complete
copies.
7. The deduced protein sequences for VP2 and VP3 were
identical in all strains and were identical to most published
sequences for natural infectious isolates of SV40.
Table 3A
Nucleotide substitutions in SV40 isolates—late region
SV40 776
position
(nucleotide)
Sequence changes identified in virus isolates relative to strain 776 Gene or
region
Ad3 Ad4 Ad7 PV Type I
1961
PV Type II
1961
PV Type I
1957
PV Type II
1957
PV Type III
1961
SV(Ad)
191
SV(Ad)
201
SV(Ad)
211
SV(Ad)
212
SV(PV)
232
SV(PV)
236
SV(PV) 241 SV(PV) 251 SV(PV) 264 SV(PV) 274
494 (G) A agno
534 (T) G IG
732 (T) A A A A A A VP2
747 (C) A VP2
768 (G) C VP2
996 (G) A VP2/3
1756 (A) C C C C C C VP1
1831 (G) A VP1
1939 (T) A A A A A A VP1
1951 (T) C C C C C C VP1
2044 (A) C VP1
2209 (G) A VP1
2215 (T) C C VP1
2239 (T) G G G G G G VP1
2268 (G) A VP1
2384 (C) A A A VP1
2581 (T) A VP1
2627–2632 6 bp del IG
2637 (T) G G IG
2668–2670 3 bp del IG
IG: intergenic region.
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had the same sequence as 776 and 777; SV(PV)241 had a
single change of a Glu to Lys at residue 54.
9. There were two major VP1 protein variants that differed at
amino acid 83 (of the mature protein). One type, the “776
type”, had a Glu at position 83, while the other type, the
“777 type”, had an Asp at this position. Six of the ten
isolates had the 777 type of VP1; the exceptions were
the archetypal versions of 776 [isolates SV(PV)236 and
SV(PV)274, which were recovered from poliovirus type
I 1961 and type III 1961, respectively] and strain SV
(Ad)201/SV(Ad)212, which was recovered from both
the Ad4 and Ad7 stocks (Tables 1 and 3). In addition,
strain SV(Ad)211, which has a 777 type of VP1, had a
Tyr in place of Cys at position 257.
10. There were two variants of small t antigen. One had the
“776 type”, with aMet at position 95 and anAla at position
109, while the other was the “777 type” with an Ile at
position 95 and a Thr at position 109. All isolates except
the archetypal versions of 776 [SV(PV)236 and SV(PV)
274] had the 777 type of small t antigen.
Discussion
The controversy over the origin of SV40 DNA sequences
found in certain human tumors and in some humans with
progressive multifocal leukoencephalopathy (PML) has con-
tinued for more than a decade and was addressed at a 2002
meeting of the Institute of Medicine (Stratton et al., 2003).
Support for the idea that SV40 could have been introduced intohumans via contaminated vaccines in the mid 1950s to the early
1960s and could have become an infectious agent of humans
comes from the following. (1) Infectious SV40 could be isolated
from both inactivated (IPV) and live, attenuated (OPV)
poliovirus vaccines (Shah and Nathanson, 1976). (2) SV40
can replicate in human cells in culture (Carbone et al., 2003;
O'Neill, 1976; Ozer et al., 1981). (3) SV40 infected and was
recovered in the throat washes from individuals inadvertently
given live SV40 as a contaminant in an experimental respiratory
syncytial virus vaccine administered via the nasal route (Morris
et al., 1961). (4) SV40 was recovered for about 5 weeks in the
stools of individuals administered SV40-contaminated OPV
(Melnick and Stinebaugh, 1962). And (5) hitherto unknown
strains of SV40 have been recovered from human tissues.
There are a number of ways that evidence could be generated
to show that contaminated vaccines were the source of the SV40
now being identified in humans. For example, if it could be
demonstrated that the strains of SV40 that have been found in
humans were the same as, and restricted to, those present in
vaccines, then this would be evidence of a link between SV40-
contaminated vaccines and those sequences found in humans. In
contrast, if the SV40 strains found in humans could not be
unambiguously assigned to vaccines, this linkage cannot be
made. The first part of this analysis depends on having the SV40-
contaminated vaccines and determining the sequences of those
strains present in them. Unfortunately, poliovirus vaccines from
that time have been difficult if not impossible to locate (Rizzo et
al., 1999b), which makes this type of analysis problematic. [We
are limiting our comments to those poliovirus vaccines
manufactured in the United States, recognizing that the polio-
Table 3B
Nucleotide substitutions in SV40 isolates—early region
SV40 776
position
(nucleotide)
Sequence changes identified in virus isolates relative to strain 776 Gene or
region
Ad3 Ad4 Ad7 PV Type I 1961 PV Type II 1961 PV Type I 1957 PV Type II 1957 PV Type III 1961
SV(Ad)
191
SV(Ad)
201
SV(Ad)
211
SV(Ad)
212
SV(PV)
232
SV(PV)
236
SV(PV) 241 SV(PV) 251 SV(PV) 264 SV(PV) 274
2717–2722 6 bp del 6 bp del T antigen
2751 (A) G G G G G T antigen
2757 (G) A A A A A A T antigen
2764–2769 6 bp del 6 bp del 6 bp del T antigen
2795/2796 9 bp ins 9 bp ins 9 bp ins 9 bp ins 9 bp ins 9 bp ins T antigen
2797 (G) C T antigen
2817 (G) A A A T antigen
2869 (C) A T antigen
2874 (A) T T T antigen
2907 (T) A A A T antigen
2917–2922 6 bp del T antigen
2918 (C) T T antigen
2922/2923 9 bp ins 9 bp ins 3 bp ins T antigen
2950 (A) G C G C G T antigen
2951 (T) C C T antigen
3117 (T) C C C C C C T antigen
3333 (G) A T antigen
3755 (A) G G G G G G T antigen
3930 (C) T T antigen
4062 (T) C T antigen
4071 (T) A A A T antigen
4110 (C) T T T T antigen
4299 (C) T T T T antigen
4308 (C) A T antigen
4579 (A) C T antigen
4642 (G) T T T T antigen
4783 (T) C t antigen
4834 (G) A A t antigen
4839 (C) T T T T T T T T t antigen
4849 (C) T T T t antigen
4879 (C) T T T T T T T T t antigen
5164 (C) T A IG
5209 (C) T T T IG
IG: intergenic region; 2795/2796 9 bp ins: TGAGGGCTG; 2922/2923 9 bp ins: TTATCATCA; 2922/2923 3 bp ins: TCA.
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contaminated with SV40 until the 1980s (Cutrone et al.,
2005).] Because we did not have SV40-contaminated vaccines,
we took an alternative approach to the problem. We reasoned
that the SV40 strains present in rhesus macaques in the United
States in the 1950s and early 1960s would be representative of
those SV40 strains that would also be in the vaccines
manufactured during this period. We had available to us
adenovirus stocks of types 3, 4, 6, and 7 that had been adapted
to replicate in primary rhesus macaque kidney cells (Hartley et
al., 1956), as well as poliovirus stocks of types I, II, and III that
had been propagated in rhesus macaque kidney cells and that
were identified at CBER. Stocks of both viruses dated from the
period when poliovirus vaccines subsequently were found to
have been contaminated by SV40 were manufactured (Table 1),
and thus these stocks met our requirement. Viruses were
recovered from all stocks except from the Ad6 stock, which had
the fewest copies of SV40 DNA of the adenovirus stocks, and
all of the poliovirus stocks except one of the type III stocks,
which had the fewest copies of SV40 DNA of the poliovirus
stocks. Whether this is because SV40 was not viable in thesestocks, or the amount of SV40 was too low, has not been
determined. Why the Ad6 stock did not produce infectious
SV40 when the number of SV40 genome copies in this stock
exceeded those present in all of the poliovirus stocks is under
investigation. It is possible that much of the SV40 DNA in some
of the adenovirus stocks is present in viruses with adenovirus/
SV40 recombinant genomes.
It is important to point out that the number of isolates we have
identified in these stocks probably represents a minimal
estimate, as there might be additional isolates present in the
stocks in lower proportions. We have only screened between 2
and 9 clones from the stocks, and thus we likely have identified
only the predominant SV40 strain(s) in any stock. In two of the
stocks, we identified two strains. In the Ad7 stock, clone pSV
(Ad)211 was found twice while clone pSV(Ad)212 was found 7
times, and in the poliovirus type I stock from 1961, clone pSV
(PV)236 was found once and clone pSV(PV)232 was found
three times. To get an idea of whether additional SV40 strains
were present in the adenovirus or poliovirus stocks, total Hirt
DNA was digested with HindIII plus BamHI and analyzed by
agarose gel electrophoresis. These results indicated that no other
Fig. 3. Alignments of the C-Terminal regions of the T antigens. (A) Alignments against strains 776 and 777 of the ten T antigens isolated from the adenovirus and
poliovirus stocks. The sequences are from Val(619) until the end of T antigen (residue 708 for strain 776). (B) Alignments of T antigens found multiple times. This
information is either from Forsman et al. (2004) or this study. Strain 777 has been isolated ten times, strain 776 has been isolated four times, strain H388/I508 has been
isolated twice, strain MC028846B has been isolated four times, and strain SV(Ad)201/SV(Ad)212 was isolated twice in this study. (C) Alignment of the C-terminal
regions of strain SV(Ad)191 and strain VA45-54.
70 K. Peden et al. / Virology 370 (2008) 63–76stocks contained more than a single virus strain, at least to the
sensitivity of this method.
Based on the sequences of their proteins, isolates SV(Ad)
201/SV(Ad)212, SV(PV)236/SV(PV)274, and SV(PV)251/SVTable 4
Sequence comparison of some isolates related to SV40 777
SV40 776
position
(nucleotide)
SV40 777
position
(nucleotide)
Sequence differences identified in virus isol
SVCPC/SVMEN GM000637H
749 (C) 677 (G) C C
849 (G) 777 (G) A A
945 (T) 873 (C) T T
1727 (C) 1655 (C) A
1831 (G) 1759 (G)
2057 (G) 1985 (G) T
2209 (G) 2137 (A)
4054 (T) 3982 (T)
5164 (C) 5101 (C)(PV)264 are three strains. Isolates SV(PV)236 and SV(PV)274
are strain 776, despite having archetype arrangements of their
enhancer elements, isolates SV(PV)251 and SV(PV)264 are
strain 777, and isolates SV(Ad)201 and SV(Ad)212 represent aates (variation from 777) Gene or
region
N128 Rh911 SV(PV)251 SV(PV)264
C C C C VP2
A VP2
T T T T VP2/VP3
VP1
A VP1
VP1
G VP1
G T antigen
A IG
Fig. 4. Structure of the control regions. The two types of control regions found in isolates recovered are represented graphically. The top sequence is from 776, with its
non-archetype arrangement of two complete copies of the 72-bp element encompassing nucleotides 107 to 250. SV(Ad)191 is representative of all but one of the
isolates and has a single copy of the 72-bp element and no alterations in the GC rich region. Isolate SV(Ad)211 is non-archetype and has a deletion of 53 bp in the
center of a duplicated enhancer element resulting in two elements, one of 45 bp (nucleotides 107 to 151) and the other of 46 bp (nucleotides 205 to 250); this isolate
also has no alteration of its GC-rich elements.
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SV(Ad)191 appears to be closely related to VA45-54, a strain
recovered from rhesus macaque kidney cells in 1960 (Forsman
et al., 2004; Sweet and Hilleman, 1960), since their T antigens
differ at only a single residue [G(651)V in SV(Ad)191 (Fig.
3C)] and the intergenic region between the VP1 gene and T
antigen gene of VA45-54 has one of the two deletions found in
SV(Ad)191 (Table 3A). Deletions in this region are uncommon.
As stated above, the original goal was to determine whether a
linkage could be made between those strains present in human
tumors and those in the vaccines. This would only be possible if
the number of circulating strains were high, since only then
would it be likely that vaccine-specific SV40 strains or
genotypes could be identified. If the number were low, then
unambiguous linkage would be difficult. There are several
indications that the repertoire of SV40 strains in rhesus
macaques in the United States might be limited.
1. Considering the number of SV40 strains that have been
described so far, either from complete genomes, from partial
sequences of infectious genomes isolated from monkeys, or
partial sequences of genomes PCR amplified from human
tissues or human tumors, there are fewer than 20 different
strains from a total of approximately 40 sequences, from both
complete and partial genomes (Forsman et al., 2004) (and
this study).
2. Several strains have been detected or their viruses isolated
more than once. For example, strain 777 has been isolated
multiple times from different sources: inactivated poliovirus
vaccine, rhesus monkey kidney cells, a patas monkey, a
meningioma, a choroid plexus tumor, a transformed cell line,
non-Hodgkin's lymphomas (Forsman et al., 2004), and
poliovirus type II and type III stocks (this work), as well as
from the defective Ad2++ HEY and Ad2++ LEY hybrids
(Lewis and Rowe, 1970) and from the SV40 large plaque
isolate of Takemoto (Takemoto et al., 1966) (Murata et al., in
press). Strain 776 has been isolated from an adenovirus type
1 seed stock (Sweet and Hilleman, 1960), an SIV-infected
monkey (Forsman et al., 2004), and from poliovirus type I
and type III stocks (this study), and from the small plaque
isolate of Takemoto et al. (1966) (Murata et al., in press).
Strain H388/I508 was isolated from different SIV-infected
macaques. Strain MC028846B was isolated from IPV dating
from 1955 (Rizzo et al., 1999b) as well as from three non-
Hodgkin's lymphomas (Forsman et al., 2004; Vilchez et al.,
2002a,b). Finally, the new SV40 strain represented byisolates SV(Ad)201 and SV(Ad)212 was recovered more
than once: from an Ad4 stock and an Ad7 stock (this study).
3. It should be noted that the Ad3, Ad4, and Ad7 viruses, as well
as the Ad2 stock, fromwhich the Ad2++ HEYand Ad2++ LEY
hybrids were recovered, were all propagated for 10 or more
serial passages in primary rhesus macaque kidney cells
(Hartley et al., 1956). Over the course of these serial passages,
multiple primary cultures were needed to sustain adenovirus
growth.We have estimated that more than 10 rhesus macaques
were necessary to provide these primary kidney cell cultures
for each of these stocks, and thus these adapted adenoviruses
had multiple opportunities to be exposed to multiple strains of
SV40. That the number of strains identified in such stocks is
limited could be taken as additional evidence for the relatively
small repertoire of SV40 strains in rhesus macaques imported
into the United States.
If the number of SV40 strains were limited in macaques
imported into the United States, then a prediction from this is that
as more isolates of SV40 are characterized, the number of times
that a previously described strain is recovered will increase and
the number of times that novel strains are recovered will
decrease. This prediction remains to be tested. We emphasize
that the possibility that the SV40 repertoire is limited only
applies to those macaques in the United States, and the situation
in macaques in their natural habitat in Asia could be different.
One reason for the limited SV40 repertoire could be that the
primate facilities in the United States represent a “closed” system
due to the proscription of animals being exported by India from
1978.
Analysis of the control region
None of the different SV40 genomes had two complete
copies of the 72-bp element, and all but one had the archetype
arrangement of a single 72-bp element and three 21-bp elements.
It has been suggested that acquisition of a second copy of the
72-bp element occurs during passage in culture (Lednicky and
Butel, 1997; Lednicky et al., 1995b; Swimmer and Shenk,
1984). Isolate SV(Ad)211 has a non-archetype arrangement but
does not have two complete copies of the 72-bp element, having
a deletion of 53 bp in the center of a duplicated enhancer element
resulting in two elements, one of 45 bp (nucleotides 107 to 151)
and the other of 46 bp (nucleotides 205 to 250) (Fig. 4); this
isolate has no alteration of its GC-rich elements. By what
mechanism (and when) SV40 strain SV(Ad)211 acquired its
72 K. Peden et al. / Virology 370 (2008) 63–76enhancer arrangement is unknown, although related complex
arrangements have been seen in other natural isolates (Ilyinskii
et al., 1992; Lednicky et al., 1998), and the large plaque variant
of Takemoto et al. (1966) also carries a small deletion between
the two elements (Murata et al., in press), which is the same as
that present in strain 777∗ (GenBank accession number
AY271817) (Forsman et al., 2004).
Changes in VP1, agnoprotein, and small t antigen
The significance of the two major VP1 alleles is not under-
stood. These changes do not appear to influence cell tropism, as
there are no known differences between 776 or 777 in their cell
tropism. Also, amino acid 83 does not appear to be part of a
neutralization epitope, since polyclonal antibodies raised to 777
and monoclonal antibodies raised to VP1 of 776 neutralize both
viruses (unpublished observations). This residue is, however,
present in one of the VP1 loops (the BC loop) (Liddington et al.,
1991) and thus is exposed on the virion surface. The additional
Cys(257) to Tyr change in the 777 type of VP1 of SV(Ad)211
represents a novel VP1 variant; the consequence of this change
has yet to be explored.
Because the major variation in SV40 VP1 is restricted to a
single amino acid, it is likely that SV40 represents a single
serotype. This is in contrast to the human polyomaviruses, BKV
and JCV, in which viruses with variant VP1 proteins have been
found (Knowles, 2006), thus raising the possibility that different
serotypes for BKV and JCV exist. Whether SV40 really is a
single serotype in its natural environment in Asia remains to be
determined.
Two alleles have been identified in the small t antigen and
agnoprotein in this study. Another allele of small t antigen has
been identified in strain VA45-54 (Stewart et al., 1996), resulting
in a total of three small t antigen sequences identified so far. All
changes are in the region that does not overlap with large T
antigen. Whether these small t antigen variants have different
activities is not known. Interestingly, the 776 type of VP1 does
not always track with the 776 type of small t antigen: strain SV
(Ad)201/SV(Ad)212 has the 776 type of VP1 but the 777 type of
small t antigen. The single amino acid substitution of Lys to Glu
at position 54 of agnoprotein in the novel strain SV(PV)241 is
the first description of this variant.
Summary and conclusions
SV40 isolates have been recovered from poliovirus and
adenovirus stocks prepared in the 1950s and early 1960s on
primary rhesus monkey kidney cells. The complete sequences of
ten cloned genomes demonstrated that five new strains have
been identified as well as strains previously identified. Because
the same strains are being isolated from rhesus macaque cells
from the 1950s to the present (e.g., 777 and 776), it is possible
that the number of SV40 strains present in colonies of rhesus
macaques in the United States is limited. The most frequently
isolated strains are archetypal versions of 776 (five times) and
777 (at least ten times). If it does turn out that the number of
SV40 strains (and genotypes) is limited in those rhesusmacaques imported into the United States, the question must
be raised as to whether it will be possible to provide un-
ambiguous evidence as to the origin of SV40 sequences found in
human tumors.
Materials and methods
Cells and viruses
CV-1 cells (obtained from the American Type Culture
Collection, Chantilly, Virginia) were grown in Dulbecco's
modified Eagle's medium (DMEM) supplemented with 10%
fetal bovine serum (FBS) and 4 mM glutamine (DMEM-10).
Stocks of adenovirus type 3 (Ad3), adenovirus type 4 (Ad4),
adenovirus type 6 (Ad6), and adenovirus type 7 (Ad7) that had
been adapted to grow in rhesus monkey kidney cells were
provided by Dr. Janet Hartley (NIAID, NIH) (Hartley et al.,
1956). Poliovirus stocks propagated on rhesus monkey kidney
cells and dating from 1957 to 1961 were discovered in a
−70 °C freezer in CBER; these stocks were independently
derived and were not part of the NIH collection. The
polioviruses in these stocks were determined by direct
sequencing to be wild-type poliovirus type I, type II, or type
III and not vaccine strains. The stocks and their dates of origin
are described in Table 1.
Recovery of SV40 from poliovirus and adenovirus stocks
To recover any SV40 present in the stocks of poliovirus and
adenovirus, it was necessary to inactivate the other virus. Both
adenovirus (Butel and Rapp, 1966; Maheshwari et al., 2004;
Svartz-Malmberg, 1964; Young, 1975) and poliovirus (Dorval et
al., 1989; French and Armstrong, 1960; Shiomi et al., 2004;
Steele and Black, 1967; Strazynski et al., 2002; Ward et al.,
1976) are sensitive to heat, adenovirus being more sensitive; in
contrast, SV40 is relatively heat resistant (Lelie et al., 1987).
Adenovirus stocks were heated to 56 °C for 10 min, while
poliovirus stocks were heated to 50 °C for 15 min. In addition,
for the poliovirus stocks, infection of CV-1 cells was done after
treatment with type-specific neutralizing monoclonal antibodies
[179-F6-G4 for type I, 13B2-1B7-G3, 7B1-2D11-A3, and 9A6-
2E4F3 for type II, and 14C4-5B12-1E12-4A5 for type III
(Singer et al., 1989)] at 1:10 dilution of the hybridoma culture
medium. Each of the stocks (0.3 mL) was used to infect CV-1
cells in T75 flasks. The appearance of cytopathic effect (CPE)
was first observed in the cultures between 8 and 20 days after
infection, and the flasks were frozen when the CPE was
extensive (+3 to +4). The freeze/thaw lysates from these
cultures provided the initial SV40 stocks.
Preparation of SV40 DNA by the Hirt method
SV40 DNAwas isolated and purified from infected cells by a
modification of the Hirt method (Hirt, 1967; Peden et al., 1980).
Briefly, CV-1 cells in T75 flasks were infected with 1 mL of the
initial SV40 stocks. When CPE (+2) was observed (days 5 to 8,
depending on the stock), the mediumwas removed, 2 mL of Hirt
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added to the cells, and the flasks were left at room temperature
for 30 min. The lysed cells were transferred using a cell scraper
to centrifuge tubes containing 600 μL of 5MNaCl. The contents
were mixed by gentle inversion several times, and the tubes were
left overnight at 4 °C. The precipitates were pelleted by centri-
fugation at 15,000 rpm in a Sorvall SS34 rotor at 4 °C for 20min,
and the supernatants were poured into 15 mL polypropylene
centrifuge tubes. Ten percent SDS was added to 0.4% (100 μL)
and proteinase K (10 mg/mL) to 50 μg/mL (12.5 μL). The tubes
were incubated at 37 °C for 6 h, and the DNAwas purified by one
phenol extraction and one phenol-CHCl3 extraction. The DNA
was precipitated by adding 3 M sodium acetate to 0.3 M
(250 μL) and 0.6 volume of iso-propanol (1.75 mL) and
incubating at −20 °C for 2.5 h. The precipitates were collected
by centrifugation at 5000 rpm for 30min at 4 °C in a Sorvall HS4
rotor. The pellets were dissolved in 300 μL of TE (10 mM Tris–
HCl, pH 8.0, 1 mMEDTA), transferred to 1.5 mL polypropylene
centrifuge tubes, and precipitated with 150 μL of 7.5 M
ammonium acetate and 1 mL ethanol and incubating at −20 °C
for 2.5 h. The precipitates were collected by centrifugation at
13,000 rpm for 10 min at 4 °C in a benchtop refrigerated
centrifuge, washed in ethanol, dried, and dissolved in 500 μL of
TE. Five microliters were analyzed on a 1% agarose gel.
Molecular cloning of the SV40 genomes
Hirt DNA (approximately 5 μg) from each infection was
digested with BamHI, and the 5-kb bands (and the 4.5 kb band
from the Ad7 stock) were gel purified using the QIAquick Gel
Extraction Kit (Qiagen, Valencia, CA) and ligated into BamHI-
digested, phosphatase-treated, and gel-purified pBluescript.
Competent DH5α cells (Invitrogen, Carlsbad, CA) were trans-
formed by the ligated DNA, and analysis of mini-prep DNAwas
used to identify colonies that harbored recombinants. At least
two clones from each ligation were chosen for further analysis.
We refer to plasmid clones of a particular strain [say, strain SV
(Ad)191] by addition of the prefix “p” [i.e., pSV(Ad)191].
Plasmids and plasmid DNA preparation
The plasmid of SV40 strain 776, pSVB3, has been described
(Peden et al., 1980), and pBluescript was from Stratagene (La
Jolla, CA). Mini-prep plasmid DNAwas prepared from 1.5 mL
cultures by the alkaline lysis method (Ish-Horowicz and Burke,
1981). Large-scale plasmid DNA was prepared from 100 mL
cultures using the Qiagen Plasmid Maxi Kit and dissolved in TE
buffer. The DNA concentrations were determined by absorbance
at 260 nm.Recovery of virus from molecular clones
Two micrograms of excised and ligated DNA in 2 mL was
phenol extracted once, adjusted to 2.5M ammonium acetate, and
ethanol precipitated. The DNA was washed in ethanol and
dissolved in 50 μL of TE. Transfection of CV-1 cells was doneusing the Qiagen PolyFect reagent according to the manufac-
turer's recommendations. Briefly, 2 μg of DNA in 50 μL of TE
was made to 100 μL in serum-free DMEM. PolyFect reagent
(40 μL) was added, and the mixture was vortex mixed for 10 s.
DMEM-10 (1 mL) was added to the tube, pipetted up and down
twice, and added to CV-1 cells in 3 mL of DMEM-10 in T25
flasks. Evidence of CPE appeared in the cultures between 7 and
10 days, and the flasks were frozen when most of the cells were
lysed (days 13 to 18). The lysates were frozen and thawed three
times and clarified by centrifugation for 10 min at 10,000 rpm at
4 °C in a Sorvall SS34 rotor to provide SV40 stocks.
Quantification of the number of viral genomes in the stocks
Real-time quantitative (Q) PCR was used to estimate the
number of SV40 genomes in the poliovirus and adenovirus
stocks. DNAwas extracted from 200 μL of the viral stocks using
NucliSens® Isolation kit (Organon Teknika Corporation,
Durham, NC) following the manufacturer's instructions. DNA
was eluted twice from silica pellets in a total volume of 100 μL.
Extracted DNA samples were diluted in TE buffer containing
CV-1 DNA (50 μg/mL) as carrier. The number of SV40 viral
genomes was determined by Q-PCR with the SL1 primer/probe
set (Pal et al., 2006) and a standard curve generated using
dilutions of the plasmid pSVB3.
Sequencing of the SV40 clones
The clones were sequenced using the Big Dye Terminator
Cycle Sequencing kit version 3.1 (ABI Prizm, Foster City, CA)
according to the manufacturer's instructions. DNA (500 ng) was
amplified for 25 cycles using 3.2 pmol of one of the sequencing
primers (Table 2). The reactions were purified using Performa
DTR Gel Filtration Cartridges from Edge Biosystems (Gaithers-
burg, MD) and fractionated on an ABI Prizm 3100 machine.
Sequences were analyzed using EditSeq and Seqman programs
(DNASTAR Inc., Madison, WI). Sequences were translated into
proteins with DNA Strider using the assigned open reading
frames (GenBank); the proteins were aligned manually.
Isolates, strains, and genotypes
Because some inconsistency is found in the literature with
respect to the use of the terms isolates, strains, genotypes, and
clades (Crandall et al., 2006; Forsman et al., 2004; Perez-Losada
et al., 2006), we describe how we have used them. We define an
isolate as any virus recovered from a source (animal, virus stock,
cell line, etc.). An isolate could be the same strain or different. A
strain is defined by the sequence of its proteins. As described by
others (Forsman et al., 2004; Lednicky et al., 1997; Stewart et al.,
1996), the C-terminal region of large T antigen is the most
variable and has been the region by which strains are designated.
In cases where genomes with the same T antigen C-terminal
sequence have a single amino acid change elsewhere, such as in
VP2, we consider these isolates at this stage as being substrains
of the same strain rather than as separate strains. The genotype is
defined by its nucleotide sequence, and thus isolates that differ in
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represent different genotypes. Therefore, strains could have
the same genotype or different. Because the control regions
(enhancer and promoter) appear to be more fluid and can mutate
in response to growth conditions in vivo (Dang et al., 2005;
Ilyinskii et al., 1992; Lednicky et al., 1998;Martin, 1989; Sack et
al., 1973) and in vitro (Lednicky and Butel, 1997, 2001;
Lednicky et al., 1995b; Swimmer and Shenk, 1984), we do not
consider their sequence or the arrangement of the elements to be
appropriate for strain assignments. Precedent for this was from
the Stoner group, where the control region was not considered
helpful for strain classification with JCV (Agostini et al., 1998).
With respect to the sequences of incomplete genomes, if the C-
terminal sequence of the T antigen corresponds to that of a
known strain, then this genome would be tentatively assigned as
belonging to that strain since other protein changes could be
present elsewhere in the genome, thus altering its strain
assignment.
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